1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Kohda, D. Fujinami, D. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C3 H7 N O2 89.093 D-ALANINE D-peptide linking C4 H9 N O2 103.120 D-ALPHA-AMINOBUTYRIC ACID D-peptide linking C4 H7 N O2 101.104 n (2Z)-2-AMINOBUT-2-ENOIC ACID Z-DEHYDROBUTYRINE peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking UK Commun Biol 2399-3642 1 150 150 10.1038/s42003-018-0150-3 30272026 The lantibiotic nukacin ISK-1 exists in an equilibrium between active and inactive lipid-II binding states. 2018 0000-0002-6763-2577 0000-0001-8234-3776 10.2210/pdb5z5q/pdb pdb_00005z5q 2970.535 Lantibiotic nukacin 1 nat polymer Bacteriocin ISK-1 no yes KKKSGVIP(DBB)V(DAL)HDCHMN(DAL)FQFVF(DBU)CCS KKKSGVIPTVAHDCHMNAFQFVFTCCS A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n sample 1 27 1292 Staphylococcus warneri database_2 pdbx_database_status pdbx_nmr_spectrometer repository Initial release Data collection Database references Other 1 0 2018-11-28 1 1 2023-06-14 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.status_code_nmr_data _pdbx_nmr_spectrometer.model Nukacin ISK-1 in active state N PDBJ Y PDBJ 2018-01-19 REL REL REL REL THR39, SER41, AND SER48 ARE DEHYDRATED TO DBB39, DAL41 AND DAL48 BY POSTTRANSLATIONAL MODIFICATIONS. target function 100 20 isotropic 1 2D 1H-1H TOCSY isotropic 1 2D 1H-1H NOESY 13 mM natural abundance 34 mM [U-2H] 10 mM natural abundance 0 mM conditions_1 3.5 pH ambient Pa 328 K simulated annealing 1 target function 13 mM nukacin ISK-1, 34 mM [U-2H] dodecylphosphocholine, 10 mM glycine, 90% H2O/10% D2O natural abundance 90% H2O/10% D2O micelle Guntert P. refinement CYANA 700 Bruker AVANCE LYS 1 n 1 LYS 1 A LYS 2 n 2 LYS 2 A LYS 3 n 3 LYS 3 A SER 4 n 4 SER 4 A GLY 5 n 5 GLY 5 A VAL 6 n 6 VAL 6 A ILE 7 n 7 ILE 7 A PRO 8 n 8 PRO 8 A DBB 9 n 9 DBB 9 A VAL 10 n 10 VAL 10 A DAL 11 n 11 DAL 11 A HIS 12 n 12 HIS 12 A ASP 13 n 13 ASP 13 A CYS 14 n 14 CYS 14 A HIS 15 n 15 HIS 15 A MET 16 n 16 MET 16 A ASN 17 n 17 ASN 17 A DAL 18 n 18 DAL 18 A PHE 19 n 19 PHE 19 A GLN 20 n 20 GLN 20 A PHE 21 n 21 PHE 21 A VAL 22 n 22 VAL 22 A PHE 23 n 23 PHE 23 A DBU 24 n 24 DBU 24 A CYS 25 n 25 CYS 25 A CYS 26 n 26 CYS 26 A SER 27 n 27 SER 27 A author_defined_assembly 1 monomeric mass spectrometry 0 0 2660 A DBU 24 modified residue A DBU 24 THR 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 identity operation 0.0000000000 0.0000000000 0.0000000000 1 A A CB SG DAL CYS 11 25 2.03 1 A A CB SG DAL CYS 18 26 2.07 2 A A CB SG DAL CYS 18 26 1.87 2 A A CB SG DAL CYS 11 25 1.94 3 A A CB SG DAL CYS 11 25 1.92 4 A A CB SG DAL CYS 11 25 1.89 4 A A CB SG DAL CYS 18 26 1.90 5 A A CB SG DAL CYS 11 25 1.89 5 A A CB SG DAL CYS 18 26 1.90 6 A A CB SG DAL CYS 11 25 1.91 7 A A CB SG DAL CYS 18 26 1.96 7 A A CB SG DAL CYS 11 25 2.03 8 A A CB SG DAL CYS 11 25 2.00 8 A A CB SG DAL CYS 18 26 2.01 9 A A CB SG DAL CYS 11 25 1.92 10 A A CB SG DAL CYS 18 26 1.89 10 A A CB SG DAL CYS 11 25 1.92 11 A A CB SG DAL CYS 11 25 1.91 11 A A CB SG DAL CYS 18 26 1.94 12 A A CB SG DAL CYS 11 25 1.91 13 A A CB SG DAL CYS 11 25 2.01 14 A A CB SG DAL CYS 11 25 1.98 14 A A CB SG DAL CYS 18 26 2.17 15 A A CB SG DAL CYS 11 25 1.94 16 A A CB SG DAL CYS 11 25 1.89 17 A A CB SG DAL CYS 18 26 1.85 17 A A CB SG DAL CYS 11 25 2.11 18 A A CB SG DAL CYS 11 25 1.86 18 A A CB SG DAL CYS 18 26 1.89 19 A A CB SG DAL CYS 18 26 1.92 19 A A CB SG DAL CYS 11 25 1.98 20 A A CB SG DAL CYS 11 25 1.91 1 A SER 4 -153.05 48.30 1 A VAL 6 -177.26 -35.40 1 A ASP 13 179.00 -32.85 1 A ASN 17 -51.21 -74.99 1 A PHE 19 -176.68 137.22 1 A GLN 20 61.68 -85.82 1 A VAL 22 33.93 48.54 1 A PHE 23 179.84 110.83 2 A LYS 2 -174.36 -44.59 2 A VAL 6 -149.17 17.64 2 A DBB 9 89.13 71.01 2 A HIS 12 -179.37 34.16 2 A ASP 13 178.96 34.98 2 A HIS 15 177.62 -50.37 2 A ASN 17 -112.32 54.70 2 A PHE 19 174.69 -71.77 2 A VAL 22 -49.08 102.41 2 A PHE 23 -177.75 -70.15 2 A CYS 25 -90.26 41.12 2 A CYS 26 -143.51 -59.74 3 A VAL 6 -149.06 17.71 3 A DBB 9 108.22 70.76 3 A HIS 12 -141.71 47.28 3 A ASP 13 -165.10 27.61 3 A HIS 15 -179.39 -174.97 3 A MET 16 -117.63 64.92 3 A ASN 17 -153.52 -45.02 3 A GLN 20 73.28 -68.42 3 A VAL 22 37.00 44.60 3 A CYS 26 -100.76 -64.59 4 A VAL 6 -149.44 18.03 4 A DBB 9 99.56 68.97 4 A DAL 11 66.31 170.11 4 A HIS 12 -96.85 38.85 4 A HIS 15 -174.89 -177.87 4 A ASN 17 -157.77 -41.28 4 A PHE 19 176.68 -73.15 4 A GLN 20 -49.41 -76.19 4 A PHE 23 -177.26 115.54 5 A VAL 6 -147.14 16.34 5 A DBB 9 109.38 63.15 5 A HIS 12 -178.55 133.48 5 A HIS 15 -156.89 -62.49 5 A MET 16 -142.09 -75.25 5 A ASN 17 -179.81 62.26 5 A PHE 19 -175.84 134.06 5 A GLN 20 69.66 -72.00 5 A PHE 21 -97.64 49.47 5 A PHE 23 -177.02 -65.92 6 A SER 4 62.00 99.04 6 A VAL 6 -142.63 24.28 6 A DBB 9 91.39 71.13 6 A HIS 12 -179.16 34.24 6 A ASP 13 -142.28 13.54 6 A ASN 17 -179.36 -34.60 6 A PHE 19 62.78 162.27 6 A GLN 20 65.25 -81.75 6 A PHE 21 -102.98 51.92 6 A VAL 22 -65.61 88.93 6 A PHE 23 -176.96 -69.79 6 A CYS 25 -92.30 37.09 7 A SER 4 57.63 -179.49 7 A ILE 7 -157.74 -61.52 7 A ASP 13 -176.05 61.88 7 A CYS 14 -160.71 -35.17 7 A HIS 15 179.82 -30.66 7 A PHE 19 64.44 152.40 7 A GLN 20 67.91 -126.50 7 A PHE 23 176.44 113.52 8 A SER 4 -150.25 47.16 8 A DBB 9 79.93 72.72 8 A HIS 12 -109.53 42.43 8 A HIS 15 -175.61 -169.44 8 A PHE 19 179.88 -81.59 8 A GLN 20 -59.83 -84.62 8 A VAL 22 -51.35 94.21 8 A PHE 23 176.62 118.38 9 A LYS 2 -163.91 90.78 9 A SER 4 -171.37 104.02 9 A VAL 6 -177.67 -32.99 9 A ASP 13 178.47 35.56 9 A MET 16 -164.35 -81.38 9 A ASN 17 177.77 35.14 9 A DAL 18 106.77 -78.27 9 A PHE 19 63.33 163.73 9 A GLN 20 65.56 -81.83 9 A PHE 21 -107.84 52.81 9 A VAL 22 -63.28 97.98 9 A PHE 23 -177.31 111.55 10 A LYS 3 -134.98 -56.89 10 A SER 4 52.35 79.36 10 A ILE 7 -157.83 -61.59 10 A HIS 12 -153.50 57.83 10 A ASP 13 -179.44 39.69 10 A HIS 15 178.52 -37.79 10 A ASN 17 -111.32 68.79 10 A PHE 19 -178.31 132.59 10 A GLN 20 64.98 -78.72 10 A PHE 23 -171.23 -49.04 10 A CYS 26 -107.03 77.11 11 A LYS 2 -95.39 53.95 11 A VAL 6 -157.76 23.02 11 A DBB 9 114.55 70.43 11 A HIS 12 179.32 142.82 11 A HIS 15 177.69 -168.31 11 A ASN 17 -148.18 -74.70 11 A DAL 18 117.10 -62.21 11 A PHE 19 64.45 -82.47 11 A GLN 20 -65.72 -113.24 11 A PHE 23 -177.78 -72.48 11 A CYS 25 -89.33 38.43 12 A LYS 2 63.13 163.47 12 A SER 4 -119.15 77.00 12 A ASN 17 -168.88 -44.79 12 A PHE 19 178.99 -68.95 12 A VAL 22 63.96 84.34 12 A PHE 23 -176.13 -69.65 13 A HIS 12 -168.31 28.85 13 A ASP 13 177.63 33.19 13 A HIS 15 -176.22 -34.10 13 A ASN 17 -90.65 47.47 13 A PHE 19 64.56 167.33 13 A GLN 20 75.68 -68.95 13 A VAL 22 37.00 44.16 13 A PHE 23 -147.22 -71.68 13 A CYS 25 -91.02 35.81 14 A LYS 3 -169.25 99.31 14 A VAL 6 -140.14 25.60 14 A DBB 9 130.62 73.05 14 A VAL 10 -104.89 -169.80 14 A HIS 12 -176.82 51.33 14 A ASP 13 -178.26 55.65 14 A CYS 14 -137.67 -46.01 14 A HIS 15 171.70 -59.18 14 A ASN 17 -151.57 61.18 14 A PHE 19 66.01 137.61 14 A GLN 20 59.69 -90.41 14 A PHE 23 -155.63 -61.62 15 A LYS 3 -145.65 33.85 15 A SER 4 -163.18 108.21 15 A DAL 11 56.17 -100.89 15 A HIS 15 171.40 118.81 15 A MET 16 50.49 -168.39 15 A ASN 17 -102.66 68.68 15 A PHE 19 -169.97 -81.74 15 A PHE 21 -167.47 27.70 15 A PHE 23 -163.18 -71.21 16 A VAL 6 -141.92 26.10 16 A DBB 9 104.56 70.56 16 A HIS 12 -175.80 32.88 16 A ASP 13 -143.56 14.38 16 A HIS 15 -177.24 -177.77 16 A MET 16 -105.24 -167.48 16 A ASN 17 73.37 -68.38 16 A GLN 20 75.67 -69.06 16 A VAL 22 35.26 79.83 16 A PHE 23 -162.79 -71.89 16 A CYS 25 -160.74 -39.37 17 A PRO 8 -69.78 -72.43 17 A DBB 9 143.46 66.55 17 A DAL 11 51.09 -104.08 17 A HIS 12 -157.76 73.10 17 A ASP 13 -135.09 -37.31 17 A CYS 14 -78.57 -77.80 17 A MET 16 62.66 161.61 17 A PHE 19 -179.43 -79.24 17 A VAL 22 65.46 127.27 17 A PHE 23 179.61 -72.72 17 A CYS 25 -160.67 -72.48 17 A CYS 26 -165.70 -80.71 18 A VAL 6 -153.50 24.77 18 A DBB 9 137.62 72.16 18 A VAL 10 -121.75 -73.85 18 A DAL 11 -55.54 176.09 18 A HIS 12 -67.59 85.87 18 A ASP 13 -156.46 -41.39 18 A CYS 14 -92.50 -81.66 18 A PHE 19 -176.79 133.32 18 A GLN 20 69.52 -72.18 18 A PHE 21 -97.86 45.07 18 A PHE 23 -176.39 -68.82 19 A LYS 2 59.30 177.29 19 A ILE 7 -157.82 -61.51 19 A HIS 12 61.65 103.48 19 A ASP 13 -179.15 -42.08 19 A CYS 14 -95.92 -73.41 19 A GLN 20 73.73 -59.48 19 A PHE 21 -107.51 -69.03 19 A VAL 22 62.61 107.22 19 A PHE 23 -165.15 -50.63 20 A LYS 2 61.25 169.44 20 A ASP 13 74.67 -59.59 20 A HIS 15 178.35 149.11 20 A MET 16 -112.26 78.20 20 A ASN 17 179.34 -33.16 20 A PHE 19 -159.24 -81.79 20 A PHE 21 -100.71 59.40 20 A PHE 23 -178.74 -70.71 N Nukacin ISK-1 in active state 1 N N covale 1.329 one A PRO 8 A C PRO 8 1_555 A DBB 9 A N DBB 9 1_555 covale 1.329 both A DBB 9 A C DBB 9 1_555 A VAL 10 A N VAL 10 1_555 covale 1.942 none A DBB 9 A CB DBB 9 1_555 A CYS 14 A SG CYS 14 1_555 covale 1.329 both A VAL 10 A C VAL 10 1_555 A DAL 11 A N DAL 11 1_555 covale 1.329 both A DAL 11 A C DAL 11 1_555 A HIS 12 A N HIS 12 1_555 covale 1.329 both A ASN 17 A C ASN 17 1_555 A DAL 18 A N DAL 18 1_555 covale 1.329 both A DAL 18 A C DAL 18 1_555 A PHE 19 A N PHE 19 1_555 covale 1.329 both A PHE 23 A C PHE 23 1_555 A DBU 24 A N DBU 24 1_555 covale 1.328 both A DBU 24 A C DBU 24 1_555 A CYS 25 A N CYS 25 1_555 ANTIBIOTIC lantibiotics, ANTIBIOTIC LANNA_STAWA UNP 1 31 Q9KWM4 KKKSGVIPTVSHDCHMNSFQFVFTCCS 31 57 5Z5Q 1 27 Q9KWM4 A 1 1 27 1 THR see sequence details DBB 9 5Z5Q A Q9KWM4 UNP 39 9 1 SER see sequence details DAL 11 5Z5Q A Q9KWM4 UNP 41 11 1 SER see sequence details DAL 18 5Z5Q A Q9KWM4 UNP 48 18